Top Page
SynAct Pharma AB
(SYNACT)
SynAct Pharma AB (SYNACT) vs. iShares MSCI Sweden ETF (EWD)
SynAct Pharma AB Business Overview & Revenue Model
SynAct Pharma AB Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -617.00K | -778.00K | -1.06M | -88.00K | 0.00 |
| EBITDA | -103.55M | -15.40M | -222.70M | -105.71M | -76.62M | -30.90M |
| Net Income | -91.07M | -82.40M | -215.81M | -99.20M | -69.30M | -26.55M |
Balance Sheet | ||||||
| Total Assets | 243.59M | 270.52M | 228.02M | 142.60M | 38.37M | 21.59M |
| Cash, Cash Equivalents and Short-Term Investments | 68.89M | 61.21M | 62.40M | 108.25M | 24.00M | 14.55M |
| Total Debt | 1.54M | 1.88M | 637.00K | 2.06M | 3.09M | 0.00 |
| Total Liabilities | 47.18M | 56.35M | 51.83M | 16.08M | 17.50M | 5.72M |
| Stockholders Equity | 196.41M | 214.17M | 176.19M | 126.52M | 20.87M | 15.87M |
Cash Flow | ||||||
| Free Cash Flow | -41.90M | -89.20M | -100.18M | -117.56M | -65.00M | -33.24M |
| Operating Cash Flow | -41.90M | -89.20M | -100.18M | -117.56M | -65.00M | -33.24M |
| Investing Cash Flow | 0.00 | 0.00 | 370.00K | 27.00K | -6.00K | -93.00K |
| Financing Cash Flow | 40.13M | 87.41M | 53.98M | 200.71M | 74.32M | 44.72M |
SynAct Pharma AB Technical Analysis
SynAct Pharma AB Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | kr3.45B | 5.35 | 167.77% | ― | 2687.51% | ― | |
56 Neutral | kr1.02B | -8.97 | -58.41% | ― | ― | 48.14% | |
55 Neutral | kr1.26B | 9.96 | 81.19% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr711.06M | -1.48 | ― | ― | 131.20% | 32.28% | |
44 Neutral | kr407.25M | -4.68 | -79.60% | ― | ― | 31.62% | |
42 Neutral | kr32.07M | -0.21 | -199.25% | ― | ― | 0.30% |
SynAct Pharma AB Corporate Events
SynAct Pharma has initiated a Phase 2 randomized, double-blind, placebo-controlled multicenter study, RESPIRE (SynAct-CS009-RESPIRE), to evaluate resomelagon in 96 patients hospitalized with respiratory insufficiency due to viral infections such as Covid-19, influenza, or RSV. Building on earlier clinical and preclinical data suggesting faster recovery, reduced intensive care needs, and mortality benefits, the trial aims to show that resomelagon can reduce severe outcomes including death, mechanical ventilation, organ support, and renal failure, thereby expanding the drug’s potential use in the hospital setting and strengthening SynAct’s dual development strategy across autoimmune disease and acute viral hyperinflammation.
The most recent analyst rating on (SE:SYNACT) stock is a Hold with a SEK25.00 price target. To see the full list of analyst forecasts on SynAct Pharma AB stock, see the SE:SYNACT Stock Forecast page.
SynAct Pharma has appointed long-serving finance executive Malin Wikstrand as interim Chief Financial Officer, effective 19 January 2026, following the departure of former CFO Björn Westberg. Wikstrand, who has been with the company since 2016 and most recently served as Financial Controller, brings extensive experience in listed-company finance and deep familiarity with SynAct’s financial structure and reporting, which management says will secure continuity and stability as the biotech advances its clinical programs. The search for a permanent CFO is under way, and the company emphasized that its overall strategy, priorities and operations remain unchanged, signalling a limited operational disruption from the leadership transition for investors and partners.
The most recent analyst rating on (SE:SYNACT) stock is a Hold with a SEK25.00 price target. To see the full list of analyst forecasts on SynAct Pharma AB stock, see the SE:SYNACT Stock Forecast page.
SynAct Pharma AB’s board has approved a share buyback program on Nasdaq Stockholm, using a mandate from a November 2025 extraordinary general meeting, to return excess liquidity to shareholders and optimize the company’s capital structure. The company plans to repurchase up to SEK 5 million of its own shares, capped at 10 percent of total outstanding shares, between 12 January and 28 February 2026, with all trades executed independently by Mangold Fondkommission under EU market abuse and safe harbour rules; the board intends to later seek shareholder approval to redeem the repurchased shares and restore share capital through a corresponding bonus issue, signaling confidence in the balance sheet while potentially enhancing value for existing investors.
The most recent analyst rating on (SE:SYNACT) stock is a Hold with a SEK23.50 price target. To see the full list of analyst forecasts on SynAct Pharma AB stock, see the SE:SYNACT Stock Forecast page.
SynAct Pharma’s board and management have voluntarily signed lock-up agreements preventing them from selling or otherwise disposing of their shares and related securities between 1 January and 30 June 2026, allowing only customary exceptions. The move comes as the company approaches key clinical milestones, including near-completion of patient recruitment and upcoming topline data from its Phase 2b ADVANCE trial in rheumatoid arthritis and a Phase 2a study in dengue virus, and is intended to underscore leadership’s confidence in SynAct’s strategy, support transparency around market-sensitive results, and signal commitment to long-term value creation for shareholders and potential partners.
SynAct Pharma AB announced that its top leadership, including the CEO, CSO, CBO, and Chairman of the Board, have collectively acquired 12,028 shares in the company on Nasdaq Stockholm, signaling internal confidence in the firm’s prospects. Management highlighted that recruitment in the company’s lead program in rheumatoid arthritis is nearing completion and that it is preparing to initiate a clinical trial in viral infection, underscoring an active late-stage pipeline and setting expectations for a data-rich 2026 that could be significant for investors and the company’s positioning within inflammatory disease therapeutics.
SynAct Pharma AB has announced the appointment of its Nomination Committee in preparation for the Annual General Meeting (AGM) 2026. The committee, comprising representatives from the three largest shareholders and the chairman of the Board, is tasked with proposing candidates for board positions and determining remuneration, reflecting the company’s commitment to transparent governance and stakeholder engagement.
SynAct Pharma announced its participation in the upcoming J.P. Morgan Healthcare Conference in San Francisco, where CEO Jeppe Øvlesen will engage with potential partners and investors. The conference presents a significant opportunity for SynAct Pharma to discuss advancements in their resomelagon treatment for rheumatoid arthritis and host-directed therapy for viral infections, potentially impacting their market positioning and stakeholder interests.
SynAct Pharma AB held an Extraordinary General Meeting where key resolutions were passed, including the implementation of an employee share option program and authorization for the Board to manage the acquisition and transfer of own shares. These measures aim to secure long-term commitment from employees and enhance the company’s capital structure, potentially increasing shareholder value.
SynAct Pharma AB announced its participation in the Redeye Autoimmune and Inflammatory Diseases event in Stockholm, where the company’s Chief Business Officer, Mads Bjerregaard, will present updates on their lead compound, resomelagon. This potential first-in-class, non-suppressive immune system modulator is being developed for treating rheumatoid arthritis and acute inflammation due to viral infections, highlighting SynAct’s innovative approach in the field of immunology.
SynAct Pharma AB has made significant progress in its Phase 2b ADVANCE study for Resomelagon, a treatment for Rheumatoid Arthritis, by randomizing 190 out of 240 patients. The study aims to evaluate the efficacy of Resomelagon in combination with methotrexate therapy, potentially offering a safer and effective alternative to current treatments, which could impact the future management of Rheumatoid Arthritis, a condition projected to affect up to 32 million people by 2050.